DUBLIN, Dec. 12, 2018 /PRNewswire/ --
The "Vaccines Market By Indication (Pneumococcal, Influenza, DTP, HPV, Hepatitis, Meningococcal, Rotavirus, Polio, MMR), Type (Live, Toxoid), Route Of Administration (IM, SC, Oral), Valence (Monovalent, Multivalent) & Geography - Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.
The global vaccines market is expected to reach $57.50 billion by 2025 from $33.70 billion in 2018, growing at a CAGR of 7.9%
The growth of this market is mainly attributed to high prevalence of diseases, increasing government initiatives towards immunization, rising adoption of vaccines, technological advancements in vaccine industry, and strong pipeline for vaccines. In addition, increasing epidemic potentials and growing focus on therapeutic vaccines are expected to offer significant growth opportunities for players operating in the vaccines market.
However, the high costs associated with vaccine development, stringent regulations and a longer timeline for vaccine development, as well as product recalls, are expected to hinder the growth of this market to a certain extent. On the other hand, the new product development cycle for vaccines and need for more training dedicated to vaccinology pose a major challenge for vaccines industry.
In 2017, pneumococcal disease accounted for the largest share of the vaccines market. The large share of this segment is mainly attributed to high prevalence of pneumococcal disease in pediatric, elderly, and immunocompromised populations. In addition, growing number of pneumococcal diseases associated with chronic disease patients is further driving the adoption of the pneumococcal vaccines.
The route of administration is the lane by which a vaccine is brought into contact with the body. Vaccines are administered through Intramuscular (IM), Subcutaneous (SC/SQ), oral, and others (intradermal and nasal). In 2017, the intramuscular accounted for the largest share of the of the global vaccines market. The large share of this segment is mainly due to availability of wide range of vaccines for IM.
Subunit, recombinant, polysaccharide, and conjugate vaccines accounted for the largest share of the global vaccines market in 2017. The large share of this segment is mainly attributed to increasing focus of companies towards recombinant and conjugate vaccines, growing prevalence of diseases, and increasing government initiatives.
An in-depth analysis of the geographical scenario of the industry provides detailed qualitative and quantitative insights about the five major geographies (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa) along with the coverage of major countries in each region.
North America accounted for largest share of vaccines market in 2017. The large share of this segment is mainly attributed to the well established vaccination program in the region, increasing prevalence of diseases, growing adoption of advanced vaccines, and large pool of key players.
The Asia-Pacific vaccines market is expected to grow at a highest CAGR of 8.9%. The growth in the APAC market is mainly attributed to large patient pool, rising prevalence of diseases, growing awareness on vaccination, increasing government initiatives, and expanding presence of key players in this region. In addition, factors such as increasing disposable income and growing awareness about heath in emerging countries are further propelling the demand of vaccines in APAC.
Key Topics Covered:
1.1. Market Definition
1.2. Market Segmentation
1.3. Currency and Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Process
2.1.1. Secondary Research
2.1.2. Primary Research
2.1.3. Market Size Estimation
3. Executive Summary
3.2. Market Dynamics
3.3. Product Segment Analysis
3.4. Regional Market Analysis
3.5. Competitive Analysis
4. Market Insights
4.1. Market Overview
4.2. Market Dynamics
4.3.1. Strong Vaccines Pipeline
4.3.2. Rising Adoption of Vaccination
4.3.3. Increasing Government Focus on Immunization Programs
4.3.4. Technological Progress in Vaccine Administration
4.4.1. High Cost Associated with Vaccine Development
4.4.2. Longer Timelines for Vaccine Manufacturing
4.5.1. Increasing Epidemic Potentials
4.5.2. Growing Focus on Therapeutic Vaccines
4.5.3. Growth Prospects in Emerging Markets
4.5.4. Increasing Use of Adjuvants in Vaccines
4.6.1. Product Recalls
4.6.2. Inadequate Access to Vaccines
5. Industry Analysis
5.1. Regulatory Analysis
5.2. Pipeline Analysis
5.3. Unmet Needs Analysis
5.4. Pricing Analysis, by Region
6. Global Vaccines Market, by Indication
6.2. Pneumococcal Disease
6.5. Human Papilloma Virus (HPV)
6.6. Meningococcal Disease
6.7. Poliomyelitis (Polio)
7. Global Vaccines Market, by Route of Administration
7.2. Intramuscular (IM)
7.3. Subcutaneous (SC)
7.5. Other (Routes of Administration)
8. Global Vaccines Market, by Type/Antigen
8.2. Subunit & Conjugate Vaccines
8.3. Inactivated Vaccines
8.4. Live Attenuated Vaccines
8.5. Toxoid Vaccines
9. Global Vaccines Market, by Valence
9.2. Multivalent Vaccines
9.3. Monovalent Vaccines
10. Vaccines Market, by Region
10.2. North America
10.3.6. Rest of Europe
10.4. Asia Pacific
10.4.4. Rest of Asia Pacific
10.5. Latin America
10.6. Middle East & Africa
11. Competitive Landscape
11.2. Competition Matrix
11.3. Market Share Analysis
11.3.1. Market Share Analysis, by Company
11.3.2. Market Share Analysis, by Product
12. Company Profiles
12.1. Sanofi Pasteur
12.2. Merck & Co., Inc.
12.3. GlaxoSmithKline Plc
12.4. Pfizer, Inc.
12.5. Johnson & Johnson
12.6. Daiichi Sankyo
12.7. Takeda Pharmaceutical Co. Ltd.
12.8. CSL Limited
12.9. Emergent BioSolutions Inc.
For more information about this report visit https://www.researchandmarkets.com/research/6f9vrx/global_vaccines?w=5
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets